Efficacy of Imiquimod Cream Administered Intraperitoneally for Ovarian Metastases in Colorectal Cancer
Yi-Hao Lin, Fu-Chieh Chu, Hsiu-Huei Peng, Hsuan Weng and Cheng-Tao Lin*
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University College of Medicine, Taoyuan, Taiwan
- Corresponding Author:
- Cheng-Tao Lin
Department of Obstetrics and Gynecology
Chang Gung Memorial Hospital
Linkou Medical Center
Chang Gung University College of Medicine, Taoyuan, Taiwan
E-mail: [email protected]
Received Date: November 02, 2016; Accepted Date: December 14, 2016; Published Date: December 20, 2016
Citation: Lin Y, Chu F, Peng H, Weng H, Lin C (2016) Efficacy of Imiquimod Cream Administered Intraperitoneally for Ovarian Metastases in Colorectal Cancer. Gynecol Obstet (Sunnyvale) 6:414. doi:10.4172/2161-0932.1000415
Copyright: © 2016 Lin Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In this case report, we sought to determine the efficacy of intraperitoneal Imiquimod cream for the treatment of persistent ovarian metastases in colorectal cancer after Avastin-based chemotherapy failure. Topical Imiquimod cream is an immune response modifier. It could trigger skin Langerhan cells (naïve dendritic cells) as the priming responsive cell type and initiate a strong Th1-switched anti-tumor cellular immune response. This is a 50-year-old woman with rectal cancer with liver, lung, left adrenal gland and ovarian metastasis, and pelvic carcinomatosis. CEA level decreased after the initial optimal debulking surgery and 12 cycles of chemotherapy. However, CEA level persistently elevated, and CT scan showed progressed carcinomatosis, malignant ascites and diffused metastasis. After intraperitoneal immunomodulatory therapy (IMT) administration with intraperitoneal Interleukin-2 mix Thymoxin on Day 1, and intraperitoneal Imiquimod cream (5% 250 mg in normal saline 2 ml) on Day 2, the amount of drainage ascites gradually decreased, and CEA level dramatically decreased after IMT.